Compass appoints a new Chief Development Officer as part of several new appointments to its management team.
Psychedelics
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Red Light Holland Announces The Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised $3,830,529 in its current private placement.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Clarmin Explorations Inc. Enters Into Amalgamation Agreement for Reverse Takeover With Cybin Corp.
Cybin Corp will become the latest psychedelics company to go public, via RTO.
Psychedelics Investing 101: Basic Investing Tips
Psychedelic drugs are an emerging sector with exciting investment potential. Here are some tips on beginning your due diligence.
Empower to Open Wellness Clinic in Vancouver, Provides Updates on Its Psychedlics Division Dosed Wellness
Empower's new wellness clinic in Vancouver will support development of its psychedelics division.
Numinus Positioned To Be Significant Player In Psilocybin R&D
Numinus Wellness Inc. has assembled the licensing and personnel to be a significant player in psilocybin-based drug research.
Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus
New psychedelics company specializing in psilocybin-based medical research has filed a prospectus.
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
MindMed files patent applications for technologies to screen and optimize dosing of MDMA and LSD.
Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
Psychedelics micro-dosing offers several key advantages over psychedelic drug applications centered around heavier dosages.
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.